SEARCH:   Advanced

Blood, 15 May 2008, Vol. 111, No. 10, pp. 5195-5204. Prepublished online as a Blood First Edition Paper on March 7, 2008; DOI 10.1182/blood-2007-09-111567. This Article Full Text (PDF) Supplemental Methods, Tables, and Figures Additional Supplemental Figures All Versions of this Article: blood-2007-09-111567v1 111/10/5195    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Xia, Y. Articles by Lin, H. Y Search for Related Content PubMed PubMed Citation Articles by Xia, Y. Articles by Lin, H. Y Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 10, 2007 Accepted February 23, 2008 Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin Yin Xia, Jodie L Babitt, Yisrael Sidis, Raymond T Chung, and Herbert Y Lin* Program in Membrane Biology and Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States Reproductive Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States * Corresponding author; email: hlin{at}partners.org. Hemojuvelin (HJV) is a co-receptor for bone morphogenetic protein (BMP) signaling that regulates hepcidin expression and iron metabolism. However, the precise combinations of BMP ligands and receptors used by HJV remain unknown. HJV has also been demonstrated to bind to neogenin, but it is not known whether this interaction has a role in regulating hepcidin expression. In the present study, we show that BMP-2, BMP-4 and BMP-6 are endogenous ligands for HJV in hepatoma-derived cells, and that all three of these ligands are expressed in human liver. We demonstrate in vitro that HJV selectively uses the BMP type II receptors ActRIIA and BMPRII, but not ActRIIB, and HJV enhances utilization of ActRIIA by BMP-2 and BMP-4. Interestingly, ActRIIA is the predominant BMP type II receptor expressed in human liver. While HJV can employ all three BMP type I receptors (ALK2, ALK3 and ALK6) in vitro, only ALK2 and ALK3 are detected in human liver. Finally, we show that HJV-induced BMP signaling and hepcidin expression are not altered by neogenin overexpression or by inhibition of endogenous neogenin expression. Thus, HJV-mediated BMP signaling and hepcidin regulation occur via a distinct subset of BMP ligands and BMP receptors, independently of neogenin. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. Kautz, D. Meynard, A. Monnier, V. Darnaud, R. Bouvet, R.-H. Wang, C. Deng, S. Vaulont, J. Mosser, H. Coppin, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver Blood, August 15, 2008; 112(4): 1503 - 1509. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020